$PBYI News

PUMA BIOTECHNOLOGY INC (NASDAQ:PBYI) Beats Q1 Estimates, Raises Full-Year Guidance

Puma Biotechnology Sees Q2 Sales $52.000M-$55.000M vs $52.000M Est

Puma Biotechnology Raises FY2026 Sales Guidance from $214.000M-$221.000M to $222.000M-$229.000M vs $218.000M Est

Puma Biotechnology Q1 Adj. EPS $(0.04) Beats $(0.13) Estimate, Sales $44.800M Beat $42.000M Estimate

As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors?

Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why

Puma Biotechnology, Inc. (PBYI) Presents at TD Cowen 46th Annual Health Care Conference - Slideshow

PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View

Puma Biotechnology, Inc. Q4 2025 Earnings Call Summary

Puma Biotechnology shares are trading lower after the company reported Q4 financial results and issued Q1 sales guidance below estimates. Also, the company issued FY26 sales guidance with its midpoint below estimates.

Puma Biotechnology shares are trading lower after the company reported Q4 financial results and issued Q1 sales guidance below estimates. Also, the company issued FY26 sales guidance with its midpoint below estimates.

Puma Biotechnology, Inc. 2025 Q4 - Results - Earnings Call Presentation

Puma Biotechnology Q4 Earnings Call Highlights

Puma Biotechnology Inc (PBYI) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic ...

Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates

Puma Biotechnology (NASDAQ:PBYI) Beats Q4 Estimates, Guides for Profitable 2026

Puma Biotech (PBYI) Earnings Call Transcript

Puma Biotech: Q4 Earnings Snapshot

Puma Biotechnology, Inc. (PBYI) Q4 2025 Earnings Call Transcript

Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results